U.S. markets closed

Renalytix Plc (RNLX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
34.78+2.41 (+7.45%)
At close: 4:00PM EDT
34.95 +0.17 (0.49%)
After hours: 06:47PM EDT

Renalytix Plc

5-7 Cranwood Street Penarth
London EC1V 9EE
United Kingdom
646 217 4999

IndustryDiagnostics & Research
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. McCullough M.B.A.CEO & Exec. Director487.72kN/A1968
Mr. Fergus FlemingCTO & Exec. Director339.95kN/A1967
Mr. Thomas H. McLainPresN/AN/A1959
Mr. Oliver James Sterling IIIChief Financial OfficerN/AN/AN/A
Ms. Andria Parks-HerreraVP of MarketingN/AN/AN/A
Dr. Sally BowdenHead of Regulatory Affairs & CBON/AN/A1970
Mr. Baljit SinghHead of Clinical OperationsN/AN/AN/A
Dr. Michael J. DonovanChief Medical OfficerN/AN/A1955
Salim HamirCompany Sec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was founded in 2018 and is based in London, the United Kingdom.

Corporate Governance

Renalytix Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.